Moderna, Inc. (MRNA)
After hours: 07:59PM EDT
| Previous Close | 331.88 |
| Open | 341.01 |
| Bid | 322.20 x 1100 |
| Ask | 322.30 x 800 |
| Day's Range | 318.50 - 341.55 |
| 52 Week Range | 65.49 - 497.49 |
| Volume | 17,153,210 |
| Avg. Volume | 19,468,982 |
| Market Cap | 130.866B |
| Beta (5Y Monthly) | 1.49 |
| PE Ratio (TTM) | 38.30 |
| EPS (TTM) | 8.46 |
| Earnings Date | Nov. 04, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 349.33 |
- Motley Fool
2 Biotech Stocks Poised for Jaw-Dropping Growth
Over the past 10 years, U.S. stocks have delivered outstanding returns for investors. The major stock indices such as the Dow Jones Industrial Average, the NASDAQ Composite, and the S&P 500 have all climbed by more than 200% during this boom period. For example, biotech innovators Axsome Therapeutics (NASDAQ: AXSM) and Moderna (NASDAQ: MRNA), along with electric-car giant Tesla (NASDAQ: TSLA), have all generated well over 1,000% returns on capital for investors in just the past three years.
- Motley Fool
Could Moderna Justify Its $129 Billion Valuation?
The company's COVID-19 vaccine has been a massive success, but how much is the underlying technology worth?
- Yahoo Finance
NIH director on why Moderna's COVID-19 vaccine for teens is on hold
Authorization for Moderna's (MRNA) COVID-19 vaccine for ages 12-17 was put on hold Friday in light of concerns over a rare side effect known as myocarditis, or a heart inflammation.
